Valerie Altavas, MD
Internal Medicine · National City, CANPI 1245231174
Payments from drug & device makers
Across 191 payments — averaging $53.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- AstraZeneca$1K
- Amgen$1K
- Johnson & Johnson$1K
- Novo Nordisk$678
- Biotronik Inc.$603
- plus $4K from 20 others
What the payments were for
- Travel & lodging$60%
- Food & beverage$10,237100%
- Education$390%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 15 | $1,504 |
| AstraZeneca | 33 | $1,386 |
| Amgen(2 entities) | 11 | $1,106 |
| Johnson & Johnson | 14 | $1,083 |
| Novo Nordisk | 15 | $678 |
| Biotronik Inc. | 5 | $603 |
| Medtronic(2 entities) | 5 | $509 |
| Abbott | 6 | $433 |
| Lilly USA, LLC | 16 | $413 |
| GSK | 4 | $383 |
| Amarin Pharma, Inc. | 11 | $333 |
| Bayer | 10 | $318 |
| Sunovion Pharmaceuticals Inc. | 5 | $270 |
| Sanofi-aventis U.S. LLC | 13 | $243 |
| Novartis | 14 | $192 |
| Edwards Lifesciences | 1 | $174 |
| Merck | 2 | $142 |
| Mannkind Corporation | 1 | $125 |
| Gilead | 1 | $120 |
| Kestra Medical Technology Services, Inc. | 1 | $105 |
| Boehringer Ingelheim | 3 | $54 |
| Valeritas, Inc. | 1 | $33 |
| Radius Health, Inc. | 1 | $25 |
| Exact Sciences | 1 | $20 |
| Pfizer | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$486
- XARELTO$482
- FARXIGA$479
- Watchman$479
- VersaCross Access Solution$288
- INVOKANA$248
- EVENITY$246
- AREXVY$244
- LONHALA MAGNAIR$243
- Vascepa$242
- RYBELSUS$232
- SAPIEN 3 Ultra RESILIA$174
- Micra$174
- Kerendia$125
- AFREZZA$125
- KRYSTEXXA$125
- TOUJEO$125
- CareLink$123
- STEGLATRO$123
- FreeStyle Libre 2$122
How this compares
$10,282 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 191 | $264,731 |
| EliquisApixaban | 127 | $142,759 |
| OzempicSemaglutide | 78 | $116,172 |
| TradjentaLinagliptin | 62 | $70,566 |
| JanuviaSitagliptin Phosphate | 41 | $47,439 |
| RybelsusSemaglutide | 18 | $42,902 |
| TrulicityDulaglutide | 24 | $39,581 |
| ProliaDenosumab | 20 | $32,691 |
| FarxigaDapagliflozin Propanediol | 28 | $30,751 |
| InvokanaCanagliflozin | 20 | $25,723 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $19,274 |
| VascepaIcosapent Ethyl | 25 | $17,812 |
| Diclofenac Sodium | 68 | $17,804 |
| JanumetSitagliptin Phos/Metformin Hcl | 32 | $17,640 |
| Atorvastatin Calcium | 853 | $12,249 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $54 | $335,297253 claims |
| Novo NordiskOzempic, Rybelsus | $678 | $159,07496 claims |
| PfizerEliquis | $17 | $142,759127 claims |
| MerckJanuvia, Janumet | $142 | $65,07873 claims |
| Lilly USA, LLCTrulicity | $413 | $39,58124 claims |
| AmgenProlia | $1,106 | $32,69120 claims |
| AstraZenecaFarxiga | $1,386 | $30,75128 claims |
| Johnson & JohnsonInvokana | $1,083 | $25,72320 claims |
| GSKTrelegy Ellipta | $383 | $19,27422 claims |
| Sanofi-aventis U.S. LLCLantus | $243 | $1,71014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.
Other internal medicine in National City
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.